引导髓母细胞瘤走向分化终末。

Leading medulloblastoma to a differentiation end.

机构信息

Program in Developmental and Stem Cell Biology, Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.

Program in Developmental and Stem Cell Biology, Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada; Departments of Medical Biophysics and Paediatrics, University of Toronto, Toronto, ON, Canada.

出版信息

Cancer Cell. 2024 Aug 12;42(8):1331-1333. doi: 10.1016/j.ccell.2024.07.011.

DOI:10.1016/j.ccell.2024.07.011

PMID:39137724

Abstract

Effective and less toxic therapies for medulloblastoma have proved to be highly elusive. In this issue of Cancer Cell, Yang et al. show that thyroid hormone treatment leads to the activation of neurogenic differentiation factor 1 (NeuroD1) and differentiation of medulloblastoma cells through reversing EZH2-mediated transcriptional repression of NeuroD1.

摘要

对于成神经管细胞瘤而言，有效的、毒性更小的疗法一直难以寻觅。在本期《癌细胞》杂志中，Yang 等人发现甲状腺激素治疗通过逆转 EZH2 介导的 NeuroD1 转录抑制，促使神经发生分化因子 1（NeuroD1）的激活和神经母细胞瘤细胞的分化。